 BOCA RATON, Fla., Sept. 14, 2021 GLOBE NEWSWIRE -- AzurRx BioPharma, Inc. NASDAQ:AZRX, First Wave BioPharma or the Company, a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal GI diseases, today issued a letter to its shareholders from James Sapirstein, President, Chief Executive Officer and Chairman, regarding its recently announced merger with First Wave Bio, Inc. and adoption of the First Wave BioPharma name. The full text of the letter, which has also been posted to the Companys website, is as follows: 